Arsenic trioxide in the treatment of haematological malignancies (Q35925650)

11 August 2017

1 reference

title

Arsenic trioxide in the treatment of haematological malignancies (English)

1 reference

11 August 2017

0 references

Yok-Lam Kwong

1

1 reference

PubMed ID

15500417

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

Expert Opinion on Drug Safety

11 August 2017

1 reference

11 August 2017

3

1 reference

11 August 2017

6

1 reference

11 August 2017

589-597

1 reference

How acute promyelocytic leukaemia revived arsenic

11 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Acute promyelocytic leukemia: evolving therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Arsenic inhibition of telomerase transcription leads to genetic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Torsade de pointes and T-U wave alternans associated with arsenic poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Prolongation of cardiac repolarization by arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Effect of Arsenic Trioxide on QT Interval in Patients With Advanced Malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Severe neurotoxicity following arsenic therapy for acute promyelocytic leukemia: potentiation by thiamine deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Chronic arsenic poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with all-trans retinoic acid: a report by the Gruppo Italiano Malattie Ematologiche dell'Adulto

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.6.589

21 January 2018

Identifiers

DOI

10.1517/14740338.3.6.589

1 reference

11 August 2017

1 reference

PubMed ID

15500417